-54.7%
OKLO vs MRNA
+485.7%
-540.4%
-79.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.2% | +5.4% | -14.6% | -9.6% |
| 7D | -12.2% | -1.1% | -11.2% | -12.2% |
| 30D | -19.7% | +126.1% | -145.9% | -28.3% |
| 3M | -37.4% | +190.0% | -227.4% | -49.5% |
| 6M | -42.3% | +157.2% | -199.5% | -51.9% |
| YTD | -49.5% | +388.2% | -437.7% | -64.7% |
| 1Y | -54.7% | +467.0% | -521.7% | -68.3% |
| All | -54.7% | +485.7% | -540.4% | -68.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling